AIM: To assess cultured limbal epithelial stem cell transplantation in patients with limbal stem cell deficiency by analyzing and quantifying corneal neovascularization.METHODS: This retrospective, interventional case...AIM: To assess cultured limbal epithelial stem cell transplantation in patients with limbal stem cell deficiency by analyzing and quantifying corneal neovascularization.METHODS: This retrospective, interventional case series included eight eyes with total limbal stem cell deficiency. Ex vivo limbal epithelial stem cells were cultured on human amniotic membrane using an animalfree culture method. The clinical parameters of limbal stem cell deficiency, impression cytology, and quantification of corneal neovascularization were evaluated before and after cultured limbal stem cell transplantation. The area of corneal neovascularization,vessel caliber(VC), and invasive area(IA) were analyzed before and after stem cell transplantation by image analysis software. Best-corrected visual acuity(BCVA),epithelial transparency, and impression cytology were also measured.RESULTS: One year after surgery, successful cases showed a reduction(improvement) of all three parameters of corneal neovascularization [neovascular area(NA), VC, IA], while failed cases did not. NA decreased a mean of 32.31%(P =0.035), invasion area29.37%(P =0.018) and VC 14.29%(P =0.072). BCVA improved in all eyes(mean follow-up, 76 ±21mo).Epithelial transparency improved significantly from 2.00 ±0.93 to 0.88±1.25(P =0.014). Impression cytology showed that three cases failed after limbal epithelial stem cell therapy before 1y of follow-up.CONCLUSION: This method of analyzing andmonitoring surface vessels is useful for evaluating the epithelial status during follow-up, as successful cases showed a bigger reduction in corneal neovascularization parameters than failed cases. Using this method,successful cases could be differentiated from failed cases.展开更多
Corneal neovascularization(CNV) is one of the major factors for vision impairment and blindness worldwide. The current treatment for CNV focuses primarily on topical eyedrops of glucocorticoids,non-steroidal anti-infl...Corneal neovascularization(CNV) is one of the major factors for vision impairment and blindness worldwide. The current treatment for CNV focuses primarily on topical eyedrops of glucocorticoids,non-steroidal anti-inflammatory drugs, electro-coagulation and laser photo-coagulation. Unfortunately,coagulation-based treatment is restricted by corneal hemorrhage and iris atrophy. And drug treatments have limited therapeutic effects and a short duration of action. Nanoparticle-based drug delivery systems are widely applied due to their improved pharmacokinetics, optimized drug targeting and enhanced biocompatibility. In this article, we provide a comprehensive and systematic overview of the CNV nanodrug system, highlighting some of the recent advances in nanodrug design, preparation, and functional modification. Moreover, we discuss the challenges in the clinical translation and potential risks in CNV treatment. A greater effort is needed for the potential applications of nanotechnology in the field of ophthalmology.展开更多
Angiogenesis refers to new blood vessels that originate from pre-existing vascular structures.Corneal neovascularization which can lead to compromised visual acuity occurs in a wide variety of corneal pathologies.A la...Angiogenesis refers to new blood vessels that originate from pre-existing vascular structures.Corneal neovascularization which can lead to compromised visual acuity occurs in a wide variety of corneal pathologies.A large subset of measures has been advocated to prevent and/or treat corneal neovascularization with varying degrees of success.These approaches include topical corticosteroid administration,laser treatment,cautery,and fine needle diathermy.Since the imbalance between proangiogenic agents and antiangiogenic agents primarily mediate the process of corneal neovascularization,recent therapies are intended to disrupt the different steps in the synthesis and actions of proangiogenic factors.These approaches,however,are only partially effective and may lead to several side effects.The aim of this article is to review the most relevant treatments for corneal neovascularization available so far.展开更多
Objective To investigate endostatin gene therapy of rat corneal neovascularization induced by acid cauterization. Methods pBlast-hEndostatin and pBlast-Mcs were identified by digestion with Nhe Ⅰand Sal Ⅰ, by PCR re...Objective To investigate endostatin gene therapy of rat corneal neovascularization induced by acid cauterization. Methods pBlast-hEndostatin and pBlast-Mcs were identified by digestion with Nhe Ⅰand Sal Ⅰ, by PCR reaction, by sequence, and then by alignment of PCR products with the geneBank using NCBIBLAST software. They were then purified with QIAGEN Endofree plasmid maxi kit. Rat corneal neovascularization models were made with 75% AgNO 3 and 25% KNO 3 cauterization. The treatment method was subconjunctive injection of the pBlast-hEndostatin with the control of pBlast-Mcs. Results pBlast-hEndostatin was found to contain the human endostatin gene. The rat corneal neovascularization induced by acid cauterization was significantly suppressed after subconjunctive injection of the pBlast-hEndostatin with inhibition rates of 37%, 40.2%, and 42.8% respectively on the sixth, tenth, and fifteenth day. The inhibition rate for the density of corneal neovascularization was 40%. However, no inhibition effect on the length of the neovascularization and corneal inflammatory cells was observed. Corneal neovascularization areas were positively correlated with edema and corneal opacity.Conclusions The plasmid of pBlast-hEndostatin contained the human endostatin gene. The rat corneal neovascularization induced by acid cauterization can be partially inhibited by subconjunctive injection of the pBlast-hEndostatin mediated by liposomes. Endostatin produced by transfected fibroblast cells directly inhibits corneal neovascularization. This is not caused by inflammatory reaction inhibition.展开更多
文摘AIM: To assess cultured limbal epithelial stem cell transplantation in patients with limbal stem cell deficiency by analyzing and quantifying corneal neovascularization.METHODS: This retrospective, interventional case series included eight eyes with total limbal stem cell deficiency. Ex vivo limbal epithelial stem cells were cultured on human amniotic membrane using an animalfree culture method. The clinical parameters of limbal stem cell deficiency, impression cytology, and quantification of corneal neovascularization were evaluated before and after cultured limbal stem cell transplantation. The area of corneal neovascularization,vessel caliber(VC), and invasive area(IA) were analyzed before and after stem cell transplantation by image analysis software. Best-corrected visual acuity(BCVA),epithelial transparency, and impression cytology were also measured.RESULTS: One year after surgery, successful cases showed a reduction(improvement) of all three parameters of corneal neovascularization [neovascular area(NA), VC, IA], while failed cases did not. NA decreased a mean of 32.31%(P =0.035), invasion area29.37%(P =0.018) and VC 14.29%(P =0.072). BCVA improved in all eyes(mean follow-up, 76 ±21mo).Epithelial transparency improved significantly from 2.00 ±0.93 to 0.88±1.25(P =0.014). Impression cytology showed that three cases failed after limbal epithelial stem cell therapy before 1y of follow-up.CONCLUSION: This method of analyzing andmonitoring surface vessels is useful for evaluating the epithelial status during follow-up, as successful cases showed a bigger reduction in corneal neovascularization parameters than failed cases. Using this method,successful cases could be differentiated from failed cases.
基金supported by the National Natural Science Foundation of China(NSFC,Nos.81901876,81925019,81801817,and U1705281)Guangdong Basic and Applied Basic Research Foundation(No.2114050002159)+1 种基金Shenzhen Science and Technology Program(No.JCYJ20210324121801004)National College Student Innovation and Entrepreneurship Training Program(No.202012631001)。
文摘Corneal neovascularization(CNV) is one of the major factors for vision impairment and blindness worldwide. The current treatment for CNV focuses primarily on topical eyedrops of glucocorticoids,non-steroidal anti-inflammatory drugs, electro-coagulation and laser photo-coagulation. Unfortunately,coagulation-based treatment is restricted by corneal hemorrhage and iris atrophy. And drug treatments have limited therapeutic effects and a short duration of action. Nanoparticle-based drug delivery systems are widely applied due to their improved pharmacokinetics, optimized drug targeting and enhanced biocompatibility. In this article, we provide a comprehensive and systematic overview of the CNV nanodrug system, highlighting some of the recent advances in nanodrug design, preparation, and functional modification. Moreover, we discuss the challenges in the clinical translation and potential risks in CNV treatment. A greater effort is needed for the potential applications of nanotechnology in the field of ophthalmology.
文摘Angiogenesis refers to new blood vessels that originate from pre-existing vascular structures.Corneal neovascularization which can lead to compromised visual acuity occurs in a wide variety of corneal pathologies.A large subset of measures has been advocated to prevent and/or treat corneal neovascularization with varying degrees of success.These approaches include topical corticosteroid administration,laser treatment,cautery,and fine needle diathermy.Since the imbalance between proangiogenic agents and antiangiogenic agents primarily mediate the process of corneal neovascularization,recent therapies are intended to disrupt the different steps in the synthesis and actions of proangiogenic factors.These approaches,however,are only partially effective and may lead to several side effects.The aim of this article is to review the most relevant treatments for corneal neovascularization available so far.
基金ThisstudywassupportedbyGuangdongProvinceMedicalScienceandTechnologyResearchFund (No .B2 0 0 0 0 5 1)
文摘Objective To investigate endostatin gene therapy of rat corneal neovascularization induced by acid cauterization. Methods pBlast-hEndostatin and pBlast-Mcs were identified by digestion with Nhe Ⅰand Sal Ⅰ, by PCR reaction, by sequence, and then by alignment of PCR products with the geneBank using NCBIBLAST software. They were then purified with QIAGEN Endofree plasmid maxi kit. Rat corneal neovascularization models were made with 75% AgNO 3 and 25% KNO 3 cauterization. The treatment method was subconjunctive injection of the pBlast-hEndostatin with the control of pBlast-Mcs. Results pBlast-hEndostatin was found to contain the human endostatin gene. The rat corneal neovascularization induced by acid cauterization was significantly suppressed after subconjunctive injection of the pBlast-hEndostatin with inhibition rates of 37%, 40.2%, and 42.8% respectively on the sixth, tenth, and fifteenth day. The inhibition rate for the density of corneal neovascularization was 40%. However, no inhibition effect on the length of the neovascularization and corneal inflammatory cells was observed. Corneal neovascularization areas were positively correlated with edema and corneal opacity.Conclusions The plasmid of pBlast-hEndostatin contained the human endostatin gene. The rat corneal neovascularization induced by acid cauterization can be partially inhibited by subconjunctive injection of the pBlast-hEndostatin mediated by liposomes. Endostatin produced by transfected fibroblast cells directly inhibits corneal neovascularization. This is not caused by inflammatory reaction inhibition.
